Parabilis Medicines (PBLS) closed at $28.53 on November 6, 2026, up 2.3% from the previous close, on volume of 610,437 shares (30-day average 1,020,210).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Parabilis Medicines to Participate in Upcoming November Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Sat, 24-Oct 8:44 AM ET)
Market Chameleon (Mon, 19-Oct 7:34 AM ET)
PBLS Sets an October 24 Stage for Updated Zolucatetide Data in Desmoid Tumors at ESMO 2026
Market Chameleon (Mon, 19-Oct 3:11 AM ET)
Globe Newswire (Mon, 19-Oct 7:00 AM ET)
Globe Newswire (Wed, 14-Oct 7:00 AM ET)
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Globe Newswire (Tue, 25-Aug 7:00 AM ET)
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 13-Aug 7:00 AM ET)
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ß-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/ß-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Parabilis Medicines trades on the NASDAQ stock market under the symbol PBLS.
As of November 6, 2026, PBLS stock price climbed to $28.53 with 610,437 million shares trading.
PBLS has a beta of -0.49, meaning it tends to be less sensitive to market movements. PBLS has a correlation of 0.01 to the broad based SPY ETF.
PBLS has a market cap of $3.52 billion. This is considered a Mid Cap stock.
Last quarter Parabilis Medicines reported $148,000 in Revenue and -$2.32 earnings per share. This fell short of revenue expectation by $-17 million and missed earnings estimates by -$2.09.
The top ETF exchange traded funds that PBLS belongs to (by Net Assets): VTI, IWM, VB, VBR, VXF.
PBLS support price is $26.25 and resistance is $29.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBLS shares will trade within this expected range on the day.
